- Home
- IBRX vs MPW Comparison
IBRX vs MPW Comparison
Compare IBRX & MPW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- MPW
- Stock Information
- Founded
- IBRX 2014
- MPW 2003
- Country
- IBRX United States
- MPW United States
- Employees
- IBRX N/A
- MPW N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- MPW Real Estate Investment Trusts
- Sector
- IBRX Health Care
- MPW Real Estate
- Exchange
- IBRX Nasdaq
- MPW Nasdaq
- Market Cap
- IBRX 2.3B
- MPW 2.5B
- IPO Year
- IBRX N/A
- MPW 2005
- Fundamental
- Price
- IBRX $2.44
- MPW $4.09
- Analyst Decision
- IBRX Strong Buy
- MPW Hold
- Analyst Count
- IBRX 5
- MPW 6
- Target Price
- IBRX $11.40
- MPW $5.67
- AVG Volume (30 Days)
- IBRX 7.6M
- MPW 9.4M
- Earning Date
- IBRX 08-05-2025
- MPW 07-31-2025
- Dividend Yield
- IBRX N/A
- MPW 7.69%
- EPS Growth
- IBRX N/A
- MPW N/A
- EPS
- IBRX N/A
- MPW N/A
- Revenue
- IBRX $56,600,000.00
- MPW $1,395,495,000.00
- Revenue This Year
- IBRX $567.98
- MPW N/A
- Revenue Next Year
- IBRX $160.56
- MPW $6.17
- P/E Ratio
- IBRX N/A
- MPW N/A
- Revenue Growth
- IBRX 4227.22
- MPW 90.73
- 52 Week Low
- IBRX $1.83
- MPW $3.51
- 52 Week High
- IBRX $7.48
- MPW $6.55
- Technical
- Relative Strength Index (RSI)
- IBRX 40.38
- MPW 41.40
- Support Level
- IBRX $2.33
- MPW $4.01
- Resistance Level
- IBRX $2.46
- MPW $4.44
- Average True Range (ATR)
- IBRX 0.15
- MPW 0.18
- MACD
- IBRX -0.03
- MPW 0.01
- Stochastic Oscillator
- IBRX 14.10
- MPW 11.90
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About MPW Medical Properties Trust Inc. common stock
Medical Properties Trust Inc acquires and develops net-leased healthcare facilities. Its investments in healthcare real estate, other loans, and any investments in tenants are considered a single reportable segment. The group's geographic areas are the United States, the United Kingdom, and All other countries.